WO2011136434A1 - Concentré de culture liquide de cellules souches dérivées d'un tissu adipeux humain ayant un effet de régénération de la peau ou d'atténuation des rides, et son utilisation - Google Patents

Concentré de culture liquide de cellules souches dérivées d'un tissu adipeux humain ayant un effet de régénération de la peau ou d'atténuation des rides, et son utilisation Download PDF

Info

Publication number
WO2011136434A1
WO2011136434A1 PCT/KR2010/003553 KR2010003553W WO2011136434A1 WO 2011136434 A1 WO2011136434 A1 WO 2011136434A1 KR 2010003553 W KR2010003553 W KR 2010003553W WO 2011136434 A1 WO2011136434 A1 WO 2011136434A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
stem cells
wrinkle
serum
Prior art date
Application number
PCT/KR2010/003553
Other languages
English (en)
Korean (ko)
Inventor
김동수
박예형
Original Assignee
(주)프로스테믹스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)프로스테믹스 filed Critical (주)프로스테믹스
Publication of WO2011136434A1 publication Critical patent/WO2011136434A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Definitions

  • the present invention relates to a culture concentrate of human adipose derived stem cells having a skin regeneration or wrinkle improvement effect, and more particularly, to culturing human adipose derived stem cells in a serum medium and then passaged in a serum-free medium.
  • a composition for skin regeneration or wrinkle improvement comprising the stem cell culture concentrate obtained by filtration as an active ingredient, the method for topical application or intradermal injection of the composition on the wound site, wrinkle removal of the composition Wrinkle improvement method, characterized in that the topical application or intradermal injection to the area that needs, a skin regeneration or wrinkle improvement treatment comprising the composition as an active ingredient, and skin regeneration or wrinkles comprising the composition as an active ingredient Relates to improving cosmetics.
  • the skin consists of the epidermis, the dermis and the subcutaneous tissue.
  • the epidermis the outer layer of skin, consists of the stratified squamous epithelium and acts as a protective barrier for the body to the outside environment.
  • the epidermis is divided from the outside into stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum basale.
  • the dermis is the layer between the epidermis and the subcutaneous tissue, divided into papillary and reticular dermis, blood vessels, collagen, elastin fibers, pores, hair roots, sebaceous glands, Korean glands, various Sensory nerves, fibroblasts and macrophages are present and occupy the largest part of the skin.
  • the dermis consists primarily of collagen and elastin fibers, which support the skin. Therefore, when such a problem occurs in the dermis, wrinkles occur and skin elasticity is lost, thereby aging the skin.
  • Collagen is known to play the most important role in skin regeneration, skin moisture content, wound healing and wrinkle improvement, and is produced from fibroblasts. Collagen has a function that can contain a large amount of moisture, which serves to supply moisture to the dermis. When aging, the collagen loses its water-containing function and wrinkles increase. Collagen can also heal wounds by filling fibroblasts with sustained collagen production when the wound is injured.
  • Stem cells are cells that have been differentiated into specific cells without progress and, if necessary, have the ability to differentiate into all kinds of cells constituting the body such as nerves, blood, and cartilage.
  • There are two ways to obtain such stem cells firstly from embryos derived from fertilized eggs (embryonic stem cells) and secondly from stem cells (adult stem cells) stored in each part of our adult body. ) Is recovered.
  • embryonic stem cells Although functionally different, both embryonic and adult stem cells have the ability to differentiate into different cell types.
  • Embryonic stem cells have very good differentiation ability and long telomeres, but they have ethical problems and difficult to obtain a large amount of cells.
  • adult stem cells can obtain a large number of cells, but can be transplanted to others. The risk of infection or differentiation is relatively low.
  • Korean Patent No. 10-0883565 discloses an injection additive for tissue regeneration using adipose derived stem cells
  • Korean Patent Publication No. 2008-0079256 discloses a composition for treating skin defects using mesenchymal stem cells.
  • the present invention is derived from the above requirements, the present inventors cultured human adipose derived stem cells in serum medium and then subcultured in serum-free medium, the stem cell culture concentrate obtained by filtration is skin regeneration or wrinkles
  • the present invention has been found to be effective for improvement.
  • the present invention cultivated human adipose derived stem cells in serum medium and then passaged in serum-free medium, skin regeneration or wrinkle improvement containing the stem cell culture concentrate obtained by filtration as an active ingredient It provides a composition for.
  • the present invention provides a method for regenerating the skin, characterized in that the composition is applied topically or intradermal injection to the wound site.
  • the present invention provides a method for improving wrinkles, characterized in that the composition is applied topically or intradermal injection to the site that needs to remove wrinkles.
  • the present invention also provides a therapeutic agent for skin regeneration or wrinkle improvement comprising the composition as an active ingredient.
  • the present invention provides a skin regeneration or wrinkle improvement cosmetics comprising the composition as an active ingredient.
  • the culture concentrate of human adipose derived stem cells of the present invention has an activity of inducing wound healing and production of type 1 procollagen, it is expected to be effectively used for skin regeneration or wrinkle improvement.
  • Figure 2 shows the results of analyzing the wound healing effect of AAPE by measuring the area of the wound site remaining in the hairless mouse artificially induced the wound.
  • Figure 3 shows the wound healing effect of AAPE in the hairless mouse artificially induced wounds through histological analysis.
  • Figure 4 shows the effect of AAPE and L- ascorbic acid on the production rate of type 1 procollagen in human dermal fibroblasts. **: Significance test of the test group against the negative control (Dunnett's t-test, p ⁇ 0.01).
  • the present invention is a skin regeneration containing the stem cell culture concentrate obtained by filtration after culturing human adipose derived stem cells in serum medium and then subcultured in serum-free medium or It provides a composition for improving wrinkles.
  • the stem cell culture concentrate is preferably
  • (d) may be prepared by filtering the culture solution.
  • Steps (b) and (c) may be performed in combination under conditions in which maximum production of human growth factors occurs.
  • stem cell culture concentrate refer to Korean Patent Publication No. 2008-0109725, which is incorporated herein by reference in its entirety.
  • the serum-free medium may preferably be a mixed medium (see Korean Patent Publication No. 2008-0109725) of Dulbecco's Modified Eagle's Medium (DMEM) and Ham's F-12 nutrient mixture,
  • DMEM Dulbecco's Modified Eagle's Medium
  • the mixing ratio may preferably be 1: 1 with DMEM and Ham's F-12 nutrient mixture.
  • composition of the present invention may exhibit skin regeneration or wrinkle improvement by increasing the production of type 1 procollagen in dermal fibroblasts.
  • the stem cells refer to undifferentiated cells having the ability to differentiate into various types of tissue cells, and are separated from embryonic stem cells and adult tissues separated from the inner cell mass of the blastocyst. It can be broadly classified into adult stem cells.
  • Adult stem cells refer to undifferentiated cells having mutipotency derived from adult tissues of mammals including humans, preferably humans. For example, various stem cells such as bone marrow, blood, brain, skin, fat, umbilical cord blood, etc. Can be derived from adult cells.
  • the human adipose derived stem cells are a kind of adult stem cells isolated from human adipose tissue. Acquisition of adipose tissue can be obtained incidentally in the process of liposuction, which is conventionally performed, and thus has an advantage of easily obtaining and culturing a sufficient amount of stem cells, and is also superior in safety to bone marrow harvesting.
  • the human adipose derived stem cells may be cultured in a conventional manner using a stem cell culture medium, for example, a serum medium.
  • a stem cell culture medium for example, a serum medium.
  • a serum medium for example, a serum medium.
  • DMEM Dulbecco's Modified Eagle's Medium
  • the protein content in the culture broth obtained can be increased.
  • the serum-free medium step minimizes the differentiation by exposing the stem cells isolated from adipose tissue to a specific extreme environment and allows the recovery of as much protein as possible from the culture medium.
  • the present invention provides a method for regenerating the skin, characterized in that the composition is applied topically or intradermal injection to the wound site.
  • the dosage form may preferably be topical application or intradermal injection, but is not limited thereto.
  • the present invention provides a method for improving wrinkles, characterized in that the composition is applied topically or intradermal injection to the site that needs to remove wrinkles.
  • the dosage form may preferably be topical application or intradermal injection, but is not limited thereto.
  • the present invention also provides a therapeutic agent for skin regeneration or wrinkle improvement comprising the composition as an active ingredient.
  • the therapeutic agent for skin regeneration or wrinkle improvement of the present invention can be applied not only to the skin for the treatment of wounds such as wounds and burns, but also to areas requiring wrinkle removal.
  • Pharmaceutically acceptable carriers included in the therapeutic agents for skin regeneration or anti-wrinkle of the present invention are commonly used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate Gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil It is not limited to this.
  • the therapeutic agent for skin regeneration or wrinkle improvement of the present invention is formulated using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by those skilled in the art to which the present invention pertains. It may be prepared in the form or incorporated into a multi-dose container, and may further include a dispersant or stabilizer.
  • the present invention provides a skin regeneration or wrinkle improvement cosmetics comprising the composition as an active ingredient.
  • Ingredients included in the skin regeneration or wrinkle improvement cosmetics of the present invention may include components commonly used in cosmetic compositions in addition to stem cell culture concentrate as an active ingredient, for example, antioxidants, stabilizers, solubilizers, vitamins, Conventional adjuvants and carriers such as pigments and perfumes.
  • the skin rejuvenation or antiwrinkle cosmetics of the present invention may be prepared in any formulations commonly prepared in the art, for example solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, cleansing and It may be formulated in a spray or the like, but is not limited thereto.
  • the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components.
  • animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components.
  • animal oils vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide
  • cellulose derivatives polyethylene glycols
  • silicones bentonites
  • silicas talc or zinc oxide
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
  • a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, and microcrystals are used as carrier components.
  • Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
  • the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether sulfate, alkyl Amidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • the skin regeneration or wrinkle improvement cosmetics of the present invention may further contain other components for the conventional skin regeneration or wrinkle improvement in addition to the stem cell culture concentrate, the type and content of these existing components can be easily selected by those skilled in the art Can be used.
  • the extracellular matrix of adipose tissue was treated with 0.075% collagenase for 45 minutes at 37 ° C. in a 5% CO 2 incubator, and then the resulting adipose tissue was centrifuged at about 1200 ⁇ g for 5 minutes to stroma. Sex vessel fractions were obtained. The obtained fractions were washed with PBS (phosphate buffered saline), other tissues were removed through a 70 ⁇ m nylon cell strainer, and histopaque-1077 (Sigma, St. Louis, MO, USA) was used to separate cell debris and mononuclear cells including red blood cells. .
  • PBS phosphate buffered saline
  • Isolated mononuclear cells were cultured with DMEM (Dulbecco's Modified Eagle's Medium; Lonza, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, USA), 1% penicillin-streptomycin (Gibco, USA). After incubation for 24 hours at 37 °C, 5% CO 2 incubator, the non-adhesive cells were removed to isolate the adipocyte stem cells.
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS fetal bovine serum
  • penicillin-streptomycin Gibco, USA
  • DMEM and Ham's F-12 nutrient mixtures were inoculated at a concentration of 1.2 ⁇ 10 6 cells / dish in a 1: 1 mixed medium (DMEM / F-12) and incubated for 72 hours under hypoxia conditions.
  • Example 3 Preparation of a culture concentrate of stem cells and fractions thereof
  • Example 2 500 mL of the culture solution finally obtained in Example 2 was centrifuged at 300 x g for 5 minutes to remove stem cells that had settled into pellets. The resulting supernatant was filtered with a 0.22 ⁇ m syringe filter to remove residual stem cells and unknown macromolecules. The obtained solution was divided in half and concentrated under reduced pressure to obtain 5 mL of concentrate (hereinafter referred to as AAPE). The resulting concentrate was lyophilized and stored at -70 ° C.
  • AAPE concentrate
  • the remaining solution from which the remaining stem cells and the unknown macromolecules are removed is passed through a membrane having a pore size of 30 kDa, and the filtrate that has not passed through the membrane is washed three times with PBS to obtain a macromolecule larger than 30 kDa.
  • solutions containing up to 30 kDa and washed PBS were again passed through a membrane having a pore size of 10 kDa to a concentrated fraction of 10 to 30 kDa and up to 10 kDa Separated into fractions. Separated 10-30 kDa fractions and at least 30 kDa fractions were stored at -70 ° C.
  • mice Female hairless mice were used to test the wound healing effect of AAPE and were performed according to the Animal Laboratory Guidelines of the National Institutes of Health (NIH). Two circular wounds with a diameter of 8 mm were artificially induced on the dorsal skin of the mouse, and then only the medium (DMEM / F-12, control) was applied to the left side, and the AAPE stock solution collected in Example 3 was applied to the right side. At the same time, the fractions obtained in Example 3 (30 kDa or more and 10 to 30 kDa) were respectively applied to the wounds of the mice. The wound healing effect was analyzed by measuring the area of the remaining wound area.
  • NASH National Institutes of Health
  • the control group coated with the medium only showed a significantly lower recovery at the early stage of the observation period compared to the experimental group treated with AAPE stock solution or fractions (FIGS. 1 and 2). .
  • AAPE stock solution or fractions In the histological examination, inflammatory cells were infiltrated in the control group and flattening of the basal layer of the epidermis was observed. Also no ridge formation was observed and the treatment was not complete (FIG. 3).
  • the skin regeneration was relatively superior to the control group during the observation period.
  • the AAPE stock treatment group showed a better effect than the other experimental group as the skin regeneration after the first three days (Figs. 1 and 2).
  • the histological findings showed that the number of inflammatory cells was significantly reduced compared to the control group, and the epidermal layer was relatively thick and the formation of rete ridges was observed, indicating that the skin regeneration effect was good (FIG. 3).
  • AAPE a culture of adipose stem cells
  • the entire AAPE fraction constituting all of them is differentiated through the first half and the second half during skin regeneration. It suggests that it has a good therapeutic activity by operating.
  • AAPE stock solution showed sufficient regeneration effect compared to the concentrated component fraction. Therefore, it is expected that the whole fraction of adipose stem cell cultured AAPE can be usefully used for symptom improvement and treatment of damaged skin.
  • DMEM mixed with 1% of an excipient penicillin-streptomycin was added to 20 ⁇ g of lyophilized AAPE, and then dissolved by vortexing.
  • a stock solution having a final concentration of 0.32 ⁇ g / mL was prepared.
  • the stock solution was diluted by azeotropy 4 to prepare a total of three concentrations (0.32, 0.08 and 0.02 ⁇ g / mL).
  • ascorbic acid L-ascorbic acid; Sigma, USA
  • ascorbic acid ascorbic acid (L-ascorbic acid; Sigma, USA) as a positive control was dissolved in the excipient was prepared at a concentration of 35.22 ⁇ g / mL (200 ⁇ M), the negative control was administered to the excipient.
  • the cell lines used in the present invention are normal human dermal fibroblasts (7F3802, Clonetics, USA), and the cell line is a complete medium (DMEM / containing 10% fetal bovine serum and 1% penicillin-streptomycin). After subculture in F-12), it was used in the experiment at 5 passages. Human dermal fibroblasts cultured in the complete medium were divided into 400 ⁇ l (1 ⁇ 10 5 cells / 400 ⁇ l / well) in 48 well plates, respectively, for 24 hours under 37 ° C. and 5% CO 2 conditions. Incubated.
  • the culture solution of each well was removed, and 500 ⁇ l of D-PBS (Dulbecco's phosphate buffered saline) was added to each well and washed. 800 ⁇ l of each preparation of the AAPE and the positive control was added to each well, and 800 ⁇ l of the excipient was added to the well of the negative control, followed by incubation for 48 hours at 37 ° C. and 5% CO 2. It was. After completion of the culture, the culture solution of each well was recovered and centrifuged at 25 ° C. and 3000 rpm for 10 minutes, and then the supernatant was taken and used for quantification of procollagen type I (procollagen type I).
  • D-PBS Dynabecco's phosphate buffered saline
  • the absorbance of each well was measured at 562 nm using an ELISA reader (PowerWave XS, BioTek, Instruments, Ins., USA). The absorbance of each well was substituted into the standard curve formula to calculate the total protein amount of the wells to which AAPE, positive control and negative control were added.
  • the obtained supernatant was placed in 100 ⁇ l into each well of a 96 well plate provided in type 1 procollagen C-peptide EIA kit (Takara Bio Inc., Japan).
  • the standard solution provided in the kit was diluted in steps to prepare 640, 320, 160, 80, 40, 20, 10 and 0 ng / mL, and then 100 ⁇ l of each was added to another well. Thereafter, the reaction was carried out in a 37 ° C. incubator for 2 hours. After completion of the reaction, the reaction solution of each well was removed, and 400 ⁇ l of PBS was added to each well, followed by washing (4 times).
  • TMBZ tetramethylbenzidine
  • a stop solution (1N H 2 SO 4
  • Absorbance was substituted into the standard curve equation to calculate the amount of type 1 procollagen in wells with AAPE, positive control and negative control. Synthesis rate of procollagen type I was calculated by substituting the corrected amount of type 1 procollagen into the following formula.
  • A Procollagen type 1 of the test substance or positive control.
  • the production rate of type 1 procollagen obtained in the present invention was assayed using a statistical program SAS (version 9.1.3, SAS Institute Inc., Cary, NC, USA). One-way analysis of variance was performed (significance level: 5%), and a multiple test of Dunnett's t-test was performed to confirm the significance of the test group to the control group (significance level; unilateral 5% and 1%). .
  • the type 1 procollagen production rate of the positive control at the concentration of 35.2 ⁇ g / mL (200 ⁇ M) was statistically significantly increased (35.2 ⁇ g / mL; 161.0 ⁇ 9.8%) compared to the negative control (FIG. 4).
  • the present invention was conducted to evaluate the type 1 collagen production promoting effect of the test substance AAPE using normal human dermal fibroblasts.
  • Treatment of human dermal fibroblasts with AAPE at 0.02, 0.08 and 0.32 ⁇ g / mL concentrations increased the production rate of type 1 procollagen in a dose-dependent manner, and the AAPE group at 0.08 and 0.32 ⁇ g / mL concentrations was negative.
  • the test material AAPE is considered to have the effect of promoting the production of collagen type 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne : une composition de régénération de la peau ou d'atténuation des rides contenant un principe actif se présentant sous la forme d'un concentré de culture liquide de cellules souches obtenu par culture de cellules souches dérivées d'un tissu adipeux humain dans un milieu de sérum, puis par passage dans un milieu sans sérum avant une filtration ; un procédé de régénération de la peau dans lequel la composition est appliquée en revêtement par voie topique ou injectée par voie intradermique à un site de lésion ; un procédé d'atténuation des rides dans lequel la composition est appliquée en revêtement par voie topique ou injectée par voie intradermique à un site où il est estimé que des lignes de rides ont besoin d'être effacées ; un agent thérapeutique de régénération de la peau ou d'atténuation des rides comprenant la composition comme principe actif ; et un produit cosmétique de régénération de la peau ou d'atténuation des rides comprenant la composition comme principe actif.
PCT/KR2010/003553 2010-04-26 2010-06-03 Concentré de culture liquide de cellules souches dérivées d'un tissu adipeux humain ayant un effet de régénération de la peau ou d'atténuation des rides, et son utilisation WO2011136434A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0038542 2010-04-26
KR1020100038542A KR101806115B1 (ko) 2010-04-26 2010-04-26 피부재생 또는 주름개선 효과를 가지는 인간 지방유래 줄기세포의 배양 농축액 및 이의 용도

Publications (1)

Publication Number Publication Date
WO2011136434A1 true WO2011136434A1 (fr) 2011-11-03

Family

ID=44861706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/003553 WO2011136434A1 (fr) 2010-04-26 2010-06-03 Concentré de culture liquide de cellules souches dérivées d'un tissu adipeux humain ayant un effet de régénération de la peau ou d'atténuation des rides, et son utilisation

Country Status (2)

Country Link
KR (1) KR101806115B1 (fr)
WO (1) WO2011136434A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103202794A (zh) * 2013-03-26 2013-07-17 广州市科玮生物技术有限公司 一种皮肤干细胞活性素的制备方法及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102311835B1 (ko) * 2018-11-20 2021-10-13 (주)프로스테믹스 줄기세포 유래 엑소좀을 포함하는 상처 치료, 피부 개선 및 탈모 방지 또는 치료용 조성물 및 그 제조방법
KR102074214B1 (ko) 2019-09-06 2020-02-06 주식회사 에이치앤비나인 경피 흡수 촉진용 구조체, 이의 제조방법 및 이를 포함하는 화장료 조성물
IL272145A (en) * 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue
KR102176935B1 (ko) 2020-04-20 2020-11-10 곽종복 주름개선 및 항염증용 화장료 조성물
KR20220035553A (ko) * 2020-09-14 2022-03-22 주식회사 시리아이앤티 노르데나우수를 이용한 기능성 화장료 조성물
JP7213479B2 (ja) * 2021-02-24 2023-01-27 株式会社Meis Technology 皮膚保護剤
KR20230078108A (ko) 2021-11-26 2023-06-02 주식회사 아리아코스메틱 면역세포 배양용 배지 조성물 및 클로토닌성분을 이용한 재생력이 향상된 마이크로바이옴 유산균 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080109725A (ko) * 2006-01-27 2008-12-17 (주)프로스테믹스 지방유래 줄기세포를 이용한 성장인자의 대량 생산방법
KR20100032099A (ko) * 2008-09-17 2010-03-25 주식회사 에스티씨라이프 줄기세포 배양액을 포함하는 화장료 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304654A1 (en) 2008-04-30 2009-12-10 Regents Of The University Of California Methods for isolating adipose-derived stem cells and therapeutic use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080109725A (ko) * 2006-01-27 2008-12-17 (주)프로스테믹스 지방유래 줄기세포를 이용한 성장인자의 대량 생산방법
KR20100036389A (ko) * 2006-01-27 2010-04-07 (주)프로스테믹스 지방유래 줄기세포 배양액을 함유하는 화장료 조성물
KR20100032099A (ko) * 2008-09-17 2010-03-25 주식회사 에스티씨라이프 줄기세포 배양액을 포함하는 화장료 조성물

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103202794A (zh) * 2013-03-26 2013-07-17 广州市科玮生物技术有限公司 一种皮肤干细胞活性素的制备方法及其应用
CN103202794B (zh) * 2013-03-26 2014-12-10 广州市科玮生物技术有限公司 一种皮肤干细胞活性素的制备方法及其应用

Also Published As

Publication number Publication date
KR20110119062A (ko) 2011-11-02
KR101806115B1 (ko) 2017-12-08

Similar Documents

Publication Publication Date Title
RU2759508C1 (ru) Композиция, включающая экзосому, полученную из стволовых клеток, для индукции адипогенной дифференцировки, регенерации жировой ткани, отбеливания кожи или коррекции морщин
WO2011136434A1 (fr) Concentré de culture liquide de cellules souches dérivées d'un tissu adipeux humain ayant un effet de régénération de la peau ou d'atténuation des rides, et son utilisation
US20210220256A1 (en) Hair growth promoting capacity of conditioned media of stimulated stem cells and use thereof
KR101293762B1 (ko) 창상치유능력이 향상된 줄기세포 배양액 및 그의 제조방법
CN110621323A (zh) 医药品组合物及化妆品组合物
KR102043739B1 (ko) 인체 지방줄기세포 배양액 추출물과 피디알앤을 함유하는 화장료 조성물
WO2015005563A1 (fr) Composition cosmétique fonctionnelle comprenant des facteurs de croissance et des acides aminés
CN113728094A (zh) 包含在含有人血小板裂解物的培养基中培养的间充质干细胞培养液的化妆品组合物
KR102341375B1 (ko) 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피부재생, 미백, 항산화 또는 상처 치료용 조성물 및 이의 용도
JP7092886B2 (ja) 鳥類の卵から分離した細胞である胚盤葉多能性幹細胞、神経幹細胞、胚性線維芽細胞条件培地を有効成分とする細胞の増殖、肌の再生、及びシワ改善用の培地組成物
EP3656850A1 (fr) Agent d'induction de cellule souche mésenchymateuse
KR20240082296A (ko) 제대혈 줄기세포에 의해 고효능의 엑소좀이 고함량으로 분비된 배양액의 제조 방법 및 이의 용도
WO2011136433A1 (fr) Milieu conditionné de cellules souches humaines dérivées de l'adipose possédant un effet de pousse de cheveux et son utilisation
KR101026070B1 (ko) 피부줄기세포의 배양방법 및 상기 배양방법으로 얻어진 피부줄기세포를 포함하는 주름개선 또는 발모촉진용 조성물
KR20220063839A (ko) 상처 치유 또는 피부 재생, 및 탈모 예방 또는 모발 성장 촉진용 중간엽 줄기세포 배양액 및 이의 제조방법
JP2021001166A (ja) 神経幹細胞培養液を有効成分として含む皮膚改善用組成物
KR20140091376A (ko) 국화 추출물을 포함하는 탈모방지 또는 발모촉진용 조성물
KR101943203B1 (ko) 지방유래줄기세포로부터 모유두 세포로의 분화방법 및 이의 용도
KR101940787B1 (ko) 진세노사이드 Rb3를 포함하는 줄기세포 배양용 배지에서 배양하여 수득된 배양액을 포함하는 상처 치료용 조성물
JP2021120398A (ja) 医薬品組成物及び化粧品組成物
KR20210063084A (ko) 체외로 분리되어 배양된 인간 줄기세포로부터 폴리디옥시리보뉴클레오티드를 분리추출하는 방법, 이에 의하여 제조된 폴리디옥시리보뉴클레오티드 및 이를 포함하는 화장료 조성물
WO2018056778A1 (fr) Composition comprenant un produit de perle fermenté pour atténuer une affection cutanée
KR101570808B1 (ko) 지방줄기세포 배양액 추출물과 하수오 줄기세포 배양 추출물을 함유하는 육모 또는 양모용 조성물
KR100874543B1 (ko) 인공피부 배양물 및 그 제조방법
JP2015020997A (ja) 幹細胞由来成長因子産生促進剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10850800

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10850800

Country of ref document: EP

Kind code of ref document: A1